|
|
||||||||
1 University Laboratory of Physiology, University of Oxford, Parks Road, Oxford OX1 3PT, United Kingdom; 2 Ecole National de Ski et d'Alpinisme, 74401 Chamonix cedex; and 3 Association pour la Recherche en Physiologie de l'Environnement, Laboratoire Réponses Cellulaires et Fonctionelles à l'Hypoxie, Université Paris XIII, 93017 Bobigny cedex, France
| |
ABSTRACT |
|---|
|
|
|---|
After a period of ventilatory
acclimatization to high altitude (VAH), a degree of hyperventilation
persists after relief of the hypoxic stimulus. This is likely, in part,
to reflect the altered acid-base status, but it may also arise, in
part, from the development during VAH of a component of carotid body
(CB) activity that cannot be entirely suppressed by hyperoxia. To test this hypothesis, eight volunteers undergoing a simulated ascent of
Mount Everest in a hypobaric chamber were acutely exposed to 30 min of
hyperoxia at various stages of acclimatization. For the second 10 min
of this exposure, the subjects were given an infusion of the CB
inhibitor, dopamine (3 µg · kg
1 · min
1). Although there was both a significant rise in
ventilation (P < 0.001) and a fall in end-tidal
PCO2 (P < 0.001) with VAH,
there was no progressive effect of dopamine infusion on these variables with VAH. These results do not support a role for CB in generating the
persistent hyperventilation that remains in hyperoxia after VAH.
hypobaric hypoxia; dopamine; carotid body; human
| |
INTRODUCTION |
|---|
|
|
|---|
VENTILATORY
ACCLIMATIZATION to high altitude (VAH) involves a progressive
rise in minute ventilation (
E) and a
fall in end-tidal PCO2
(PETCO2). The mechanisms that underlie
this process are not completely understood. Part of the process
involves an elevation of the peripheral chemoreflex sensitivity to
hypoxia (6, 16). However, not all of the VAH
can be explained by this because, after a period of acclimatization,
return to hyperoxia does not bring
E back to
baseline (5, 10). One interpretation of this
is that the residual hyperventilation in hyperoxia arises from the
alteration in acid-base status induced by the hypocapnia and that it
takes days to recover from this. However, we have observed a sustained
elevation of
E after exposure to sustained isocapnic
hypoxia, in which acid-base changes have been prevented (17, 18). In addition, Forster et al.
(7) doubt that, on exposure to acute hyperoxia following
VAH, the associated rise in PETCO2 is
quantitatively sufficient to explain the residual hyperventilation via
a mechanism involving the central chemoreceptors. Thus an alternative
explanation of the persistent hyperventilation in hyperoxia is that
carotid body (CB) function is so altered after hypoxia that there is
persistent activity, even in hyperoxia.
To investigate this possibility, the acute peripheral chemoreflex
response to hypoxia was first suppressed with the use of a hyperoxic
gas mixture at various stages of an acclimatization process. Then, on
top of this, the effect of low-dose dopamine (DA) administration (3 µg · kg
1 · min
1) was
investigated. In humans, low doses of DA substantially reduce CB-induced respiratory activity (23), a finding shown to
persist during the early stages of VAH (13). If a
component of the ventilatory acclimatization that is not readily
reversible by hyperoxia arises (at least in part) through an increase
in CB activity, then we would expect DA to become progressively more
effective in suppressing
E and elevating
PETCO2 as acclimatization proceeds. If, on
the other hand, no part of this component arises from the CB, then we
would expect no change in the effect of DA with acclimatization.
| |
METHODS |
|---|
|
|
|---|
Subjects. Nine healthy young adults, eight for the study and one reserve, were selected (age = 23-37 yr, all were men). The selection of subjects for the study was based on a number of criteria. Excellent health and physical condition were required. The subjects' motivation to participate was assessed, and psychological tests were employed to try to determine their ability to withstand confinement in a chamber for 5 wk. Medical students, doctors, or other medically related workers who had previous experience in altitude were preferred. All subjects exercised a certain amount on each day of chamber confinement. All subjects received written and verbal descriptions of the experiment before they gave their consent. The study was approved by the Marseilles Research Ethics Committee.
Acclimatization.
Eight subjects lived in a hypobaric chamber (COMEX, life chamber type
2500, length of 8 m, available volume = 32 m3) at
normal room temperature during 31 days of progressive decompression designed to simulate barometric pressure conditions during an ascent of
Mount Everest. Figure 1 illustrates the
progression profile. Before subjects entered the chamber, they spent 1 day at Refuge de Cosmique (3,650 m) and 5 days at Observatoire Vallot (4,350 m) to preacclimatize.
|
Experimental setup. All experiments were carried out in a hydrosphere (diameter = 5 m, available volume = 65 m3) that was equipped with the necessary technical facilities. Each morning, the hydrosphere was decompressed to reach the barometric pressure appropriate to the level of ascent inside the life chamber; each evening, it was recompressed to ambient pressure outside the chamber. This allowed the experimenters (who had their own oxygen supplies) to enter the hydrosphere in the morning to conduct experiments with the subjects and to leave it in the evening. A lock (COMEX, type 2000) served as the connection (and bathroom) between the life chamber and the hydrosphere. The life chamber was equipped with eight sleeping bunks and a table for meals. At 7,000 m, the subjects were sufficiently familiar with the experiments, thus allowing experimenters to supervise procedures outside the hydrosphere via a microphone.
Protocol.
For each subject, the experiment was undertaken twice before any period
of acclimatization; twice at 5,000 m [422 mmHg, inspired PO2 (PIO2) was 79 Torr], with 4 days between measurements; twice at 7,000 m (324 mmHg,
PIO2 = 58 Torr), again with 4 days
between measurements; and, finally, on days 2 and
4 after return to sea level (Fig. 1). Each experiment lasted
40 min, which meant that it took most of the day to complete the
experiments on all eight subjects. The order in which the subjects were
studied on each day was random, but the protocol was always the same
(Fig. 2). Resting pulmonary ventilation
was measured during the initial 10 min (period 1:
"air"). Hyperoxia [end-tidal PO2
(PETO2) of ~200 Torr] was
then introduced and maintained throughout the remaining 30 min. The
first 10 min of hyperoxia (period 2: "hyperoxia-1") formed an initial control period. Then, the DA infusion (3 µg · kg
1 · min
1 iv) was started and
continued for 10 min (period 3: "DA and hyperoxia"). Finally, a second 10-min control period of hyperoxia followed (period 4: "hyperoxia-2"). The dose of DA was kept the
same in all experiments on any given subject (and was based on the
subjects' weight at sea level before acclimatization). To obtain
PETO2 values of ~200 Torr, the fraction
of inspired oxygen in the hyperoxic mixture was progressively
increased. The inspired oxygen used was 30.9% at sea level, 58.7%
at 5,000 m, and 79.4% at 7,000 m.
|
Respiratory measurements.
Subjects were seated comfortably inside the hydrosphere and breathed
through a mouthpiece with the nose occluded. The mouthpiece was
connected in series with a valve so that the inspirate could be either
ambient air or the appropriate hyperoxic gas mixture from a 150-liter
Douglas bag that was filled continuously from a cylinder containing the
premixed gas. The expirate would either go to the environment or,
during hypobaria, be directed out of the hydrosphere. Expiratory
airflow was sensed with a symmetrically disposed Pitot tube flowmeter,
and
E was determined from this (14).
The gas analyzers consisted of a galvanic fuel cell for measurement of
oxygen concentration and an infrared carbon dioxide analyzer (model
CPX/D, Medical Graphics System). A pulse oximeter was attached to the
earlobe to monitor oxygen saturation (model 502, Criticare). Arterial
blood pressure was collected over 20-s intervals by an automatic
sphygmomanometer (Dinamap 1846 SX P, Criticon) to monitor any adverse
effects of the DA infusion on blood pressure. All experimental data
were recorded in real time by a computer.
Data analysis. Breath-by-breath data for each experiment were first averaged over 60-s periods. Average values for the four periods (air, hyperoxia-1, DA and hyperoxia, and hyperoxia-2) were then obtained by averaging the data for the 6th-9th min of each period (see Fig. 2). The significance of the effects of altitude, first or second repeat at each altitude, hyperoxia, and DA was assessed with the use of ANOVA, with subjects treated as a random variable and the other factors as fixed effects. A probability of P < 0.05 was taken as statistically significant. Analysis was undertaken by using the statistical software package SPSS 7.0.
| |
RESULTS |
|---|
|
|
|---|
During the preacclimatization period at Observatoire Vallot, one subject developed pulmonary edema and the reserve took his place. Of the 8 subjects entering the hypobaric chamber, three did not complete all three ascents to 8,848 m (see Fig. 1). One subject developed neurological symptoms at 8,000 m and was evacuated, one subject was evacuated after the first ascent (8,848 m), and one subject did not take part in the final ascent. The subjects all recovered within a few minutes of oxygen inhalation. All subjects entering the chamber reached the altitudes of interest for the present study. Subjects that were evacuated were studied on the 2nd and 4th day after leaving the chamber for the return-to-sea-level experiments. No subject felt any side effects from the DA infusions, and there was no change in blood pressure with the DA infusions in any subject at any altitude.
Blood measurements.
Base excess, pH, and hemoglobin concentration rose during the ascent;
the values for these variables are listed in Table
1.
|
Ventilatory responses to increasing hypobaria.
The acclimatization process was characterized by a progressive increase
in
E and fall in
PETCO2. This is illustrated in Fig.
3, along with the changes in
PETO2. The increases in
E and decreases in
PETCO2 while breathing ambient air were
significant between altitudes (P < 0.001). After 2 and
4 days at return to sea level,
E was still
significantly higher (P < 0.001) and PETCO2 was significantly lower
(P < 0.001) than before any acclimatization had
taken place.
|
E in acute hyperoxia.
Figure 4 illustrates the breath-by-breath
results from one experiment from one subject (subject 9,
experiment from the 5th day at 5,000 m). Figure 4 shows that the
induction of hyperoxia decreases
E and increases
PETCO2. Values for
E,
PETO2, and PETCO2 appear similar
between the two hyperoxic periods (hyperoxia-1 and hyperoxia-2). This
was generally true for all subjects and altitudes, with no significant
differences being detected between the two periods. Therefore, in Figs.
3 and 5, which illustrate the overall responses of the group, average
values were used for these two periods.
|
E and
PETCO2 averaged over all subjects
throughout the acclimatization process. The influence of hyperoxia on
E and
PETCO2 varied with altitude (P < 0.001). Before and after the hypobaric period,
acute hyperoxia had no significant effect on
E or
PETCO2. During the hypobaric period,
hyperoxia had significant and progressively increasing effects on
E. However, at no altitude during hypobaria or
during the return-to-sea-level measurements did hyperoxia return either
E or PETCO2 completely
to preacclimatization values.
Effects of DA on
E and
PETCO2 during acute hyperoxia.
In the single experiment illustrated in Fig. 4, DA appeared to have
little effect on either
E or
PETCO2. The effect of DA on the data
averaged from all subjects from all experimental days is shown in Fig.
5. DA, when administered on top of
hyperoxia, had no consistent effect in reversing
E
further toward its preacclimatization value. For
PETCO2, the group mean values for DA were
slightly higher than without DA; this result was consistent at all
altitudes and was significant overall (P < 0.05).
There was no progressive alteration in the effects of DA on either
E or PETCO2 as
acclimatization proceeded.
|
| |
DISCUSSION |
|---|
|
|
|---|
The major finding of this study was that DA, when infused at a low
dose in patients undergoing acute hyperoxic exposure, did not suppress
E or elevate PETCO2 in
a manner that became progressively more effective as acclimatization
proceeded. This finding does not provide any support for the hypothesis
that part of the hyperventilation that remains after VAH arises
from an increase in CB activity that persists under the newly
imposed hyperoxic state.
If a clear effect of DA on
E and
PETCO2 that became progressively more
marked with acclimatization had been demonstrated, then this study
would have provided quite compelling evidence for a peripheral origin
for some of the ventilatory stimulation that persists under hyperoxic
conditions following VAH. However, because this study did not
demonstrate such an effect, our question is this: to what extent can
the present study exclude a peripheral origin for some of the
persistent hyperpnea under hyperoxic conditions? With respect to this,
the major issue is the degree of confidence that we have that DA would
be expected to suppress residual activity at the CB under these conditions.
In anesthetized cats, infusion or injection of DA reduces both the
chemosensory discharge from the CB (11) and ventilation (11, 24). Of particular note is that these
findings were determined under hyperoxic conditions. Similar
results have been obtained in hyperoxia for
E
(3) and phrenic nerve activity (12) in awake
and anesthetized goats, respectively. In conscious humans, low-dose DA
infusion reduces both the ventilatory sensitivity to hypoxia
(1, 2, 4, 15,
20, 22, 23) and the ventilatory
sensitivity to carbon dioxide (in euoxia) (15,
21). However, in the case of effects of DA in hyperoxia in
humans, the authors are aware of only one previous study [Welsh et al. (23)], which found that low-dose DA infusion had no
effect on
E.
There are several possible interpretations of the finding of Welsh et
al. (23). It is possible that there is a genuine species difference between cats and goats on the one hand and humans on the
other hand, such that DA is an effective inhibitor of the CB under
hyperoxic conditions in the former but not in the latter. However,
there may also be a species difference such that hyperoxia is more
effective in reducing carotid chemoreceptor activity in humans than in
cats and/or goats, such that there remains little or no chemoreceptor
activity in hyperoxic humans for the low-dose DA infusion to suppress.
A third possibility is that the result of Welsh et al. arises from a
type II statistical error. There was a nonsignificant reduction in
E and elevation of
PETCO2 by low-dose infusion of DA in
hyperoxia that was around the size of the standard error, favoring this
possibility. Furthermore, the present study did manage to detect a
small but significant effect of DA on
PETCO2 in hyperoxia, if not on
E.
The previous studies cited above all relate to subjects or experimental animals that were not acclimatized to hypoxia. In rats, a 4-wk exposure to hypoxia resulted in an approximate doubling of CB diameter and protein content and a 15-fold increase in DA content (8). These changes, particularly in DA metabolism, certainly raise the possibility that the action of low-dose DA infusion may not be the same as in unacclimatized CB. In support of this notion, Tatsumi et al. (19) found in the anesthetized cat that the ability of domperidone to potentiate the ventilatory response to hypoxia was lost after VAH. However, this finding has not been replicated in subsequent studies in awake goats (9) and humans (13). In relation to the effects of low-dose DA infusion, we know of no studies that used this after a prolonged period of VAH. After a brief period of acclimatization, the percent reductions in both the ventilatory sensitivity to hypoxia and a calculated isocapnic residual ventilation in the absence of hypoxia generated by low-dose DA infusion appear similar to those found before acclimatization.
A further difference in the use of low-dose DA infusion in the present
study compared with studies of the unacclimatized state relates to
PETCO2. In the present study, all
subjects remained markedly hypocapnic in the hyperoxic exposure
compared with their preacclimatization state. Sabol and Ward
(15) found that DA was, in terms of percentage, more
effective in suppressing euoxic
E in hypercapnic
conditions than under conditions of eucapnia. Thus one possible
explanation for the results from the present study is that DA is
relatively ineffective at suppressing CB activity under conditions of hypocapnia.
In summary, we have found no evidence for a persistent stimulus to ventilation arising from the CB under conditions of acute hyperoxia generated by VAH. The results suggest that the hyperventilation that remains in acute hyperoxia essentially arises centrally, but the strength of this conclusion is limited somewhat by uncertainties as to the action of low-dose DA infusion under these particular conditions.
| |
ACKNOWLEDGEMENTS |
|---|
We thank COMEX administrative and technical staff for support of this project. We especially thank the eight volunteers who agreed to spend 31 days in confinement.
| |
FOOTNOTES |
|---|
The overall project was supported by grants from Région PACA and Ministère Jeunesse et Sport, France. P. A. Robbins held a visiting professorship from the University of Paris XIII. M. E. F. Pedersen held a Medical Research Council studentship and a scholarship from the Danish Research Academy.
This study formed part of a series of experiments associated with the COMEX 97 simulated ascent of Mount Everest.
Address for reprint requests and other correspondence: P. A. Robbins, Univ. Laboratory of Physiology, Parks Road, Oxford OX1 3PT, UK (E-mail: peter.robbins{at}physiol.ox.ac.uk).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Received 21 May 1999; accepted in final form 3 March 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Bainbridge, CW,
and
Heistad DD.
Effect of haloperidol on ventilatory responses to dopamine in man.
J Pharmacol Exp Ther
213:
13-17,
1980
2.
Bascom, DA,
Clement ID,
Dorrington KL,
and
Robbins PA.
Effects of dopamine and domperidone on ventilation during isocapnic hypoxia in humans.
Respir Physiol
85:
319-328,
1991[ISI][Medline].
3.
Bisgard, GE,
Forster HV,
Klein JP,
Manohar MM,
and
Bullard VA.
Depression of ventilation by dopamine in goats: effects of carotid body excision.
Respir Physiol
40:
379-392,
1980[ISI][Medline].
4.
Dahan, AD,
Ward D,
Elsen MVD,
Temp J,
and
Berkenbosch A.
Influence of reduced carotid body drive during sustained hypoxia on hypoxic depression of ventilation in humans.
J Appl Physiol
81:
565-572,
1996
5.
Dempsey, JA,
and
Forster HV.
Mediation of ventilatory adaptations.
Physiol Rev
62:
262-346,
1982
6.
Forster, HV,
Dempsey JA,
Birnbaum ML,
Reddan WG,
Thoden J,
Grover RF,
and
Rankin J.
Effect of chronic exposure to hypoxia on ventilatory response to CO2 and hypoxia.
J Appl Physiol
31:
586-592,
1971
7.
Forster, HV,
Dempsey JA,
and
Chosy LW.
Incomplete compensation of CSF [H+] in man during acclimatization to high altitude (4,300 m).
J Appl Physiol
38:
1067-1072,
1975
8.
Hanbauer, I,
Karoum F,
Hellstrom S,
and
Lahiri S.
Effects of hypoxia lasting up to one month on the catecholamine content in rat carotid body.
Neuroscience
6:
81-86,
1981[ISI][Medline].
9.
Janssen, P,
O'Halloran K,
Pizarro J,
Dwinell M,
and
Bisgard GE.
Carotid body dopaminergic mechanisms are functional after acclimatization to hypoxia in goats.
Respir Physiol
111:
23-32,
1998.
10.
Kellogg, RH,
Pace N,
Archibald ER,
and
Vaughan BE.
Respiratory response to inspired CO2 during acclimatization to an altitude of 12,470 feet.
J Appl Physiol
11:
65-71,
1957
11.
Nishino, T,
and
Lahiri S.
Effects of dopamine on chemoreflexes in breathing.
J Appl Physiol
50:
892-897,
1981
12.
O'Halloran, KD,
Janssen PL,
and
Bisgard GE.
Dopaminergic modulation of respiratory motor output in peripherally chemodenervated goats.
J Appl Physiol
85:
946-954,
1998
13.
Pedersen, MEF,
Dorrington KL,
and
Robbins PA.
Effects of dopamine and domperidone on ventilatory sensitivity to hypoxia after 8 h of isocapnic hypoxia.
J Appl Physiol
86:
222-229,
1999
14.
Porszasz, J,
Barstow TJ,
and
Wasserman K.
Evaluation of a symmetrically disposed Pitot tube flowmeter for measuring gas flow during exercise.
J Appl Physiol
77:
2659-2665,
1994
15.
Sabol, SJ,
and
Ward DS.
Effect of dopamine on hypoxic-hypercapnic interaction in humans.
Anesth Analg
66:
619-624,
1987
16.
Sato, M,
Severinghaus JW,
Powell FL,
Xu F-D,
and
Spellman MJ, Jr.
Augmented hypoxic ventilatory response in men at altitude.
J Appl Physiol
73:
101-107,
1992
17.
Tansley, JG,
Clar C,
Pedersen MEF,
and
Robbins PA.
The human ventilatory response to acute hyperoxia during and after 8 h of both isocapnic and poikilocapnic hypoxia.
J Appl Physiol
82:
513-515,
1997
18.
Tansley, JG,
Fatemian M,
Howard LSGE,
Poulin MJ,
and
Robbins PA.
Changes in respiratory control during and after 48 h of isocapnic and poikilocapnic hypoxia in humans.
J Appl Physiol
85:
2125-2134,
1998
19.
Tatsumi, K,
Pickett CK,
and
Weil JV.
Decreased carotid body hypoxic sensitivity in chronic hypoxia: role of dopamine.
Respir Physiol
101:
47-57,
1995[ISI][Medline].
20.
Ward, DS,
and
Bellville JW.
Reduction of hypoxic ventilatory drive by dopamine.
Anesth Analg
61:
333-337,
1982
21.
Ward, DS,
and
Bellville JW.
Effect of intravenous dopamine on hypercapnic ventilatory response in humans.
J Appl Physiol
55:
1418-1425,
1983
22.
Ward, DS,
and
Nino M.
The effects of dopamine on the ventilatory response to sustained hypoxia in humans.
In: Control of Breathing and Its Modeling Perspective, edited by Honda Y,
Miyamoto Y,
Konno K,
and Widdicombe JG.. New York: Plenum, 1992, p. 291-298.
23.
Welsh, MJ,
Heistad DD,
and
Abboud FM.
Depression of ventilation by dopamine in man.
J Clin Invest
61:
708-713,
1978.
24.
Zapata, P,
and
Zuazo A.
Respiratory effects of dopamine-induced inhibition of chemosensory inflow.
Respir Physiol
41:
79-92,
1980.
This article has been cited by other articles:
![]() |
J. H. Mateika, C. Mendello, D. Obeid, and M. S. Badr Peripheral chemoreflex responsiveness is increased at elevated levels of carbon dioxide after episodic hypoxia in awake humans J Appl Physiol, March 1, 2004; 96(3): 1197 - 1205. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |